Schedule 13D ownership disclosure
ProQR Therapeutics NV
Ordinary Shares, nominal value Euro 0.04 per share · CUSIP: N71542109
Event date: 2025-05-23
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Van Herk Investments B.V.Reported CIK 0001633120
Shares: 11,501,995.00 · Class: 10.9%
- Van Herk Investments THI B.V.
Shares: 11,501,995.00 · Class: 10.9%
- Van Herk Private Equity Investments B.V.
Shares: 11,501,995.00 · Class: 10.9%
- Stichting Administratiekantoor Penulata
Shares: 11,501,995.00 · Class: 10.9%
- Van Herk Management Services B.V.
Shares: 11,501,995.00 · Class: 10.9%
- Onroerend Goed Beheer- en Beleggingsmaatschappij A. van Herk B.V.
Shares: 11,501,995.00 · Class: 10.9%
- A. van Herk Holding B.V.
Shares: 11,501,995.00 · Class: 10.9%
- Stichting Administratiekantoor Abchrys
Shares: 11,501,995.00 · Class: 10.9%
- Adrianus van Herk
Shares: 11,501,995.00 · Class: 10.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-053336
- Form type
- SCHEDULE 13D
- Filer
- ProQR Therapeutics N.V.
- CIK
- CIK 1612940
- Filed
- May 28, 2025
- Reporting period
- May 23, 2025
- Description
- Schedule 13D beneficial ownership